New Elite Feature: Chart Templates — Your indicators and design everywhere on Finviz

Zai Lab Limited (ZLAB) Stock Jumps 6.8%: Will It Continue to Soar?

By Zacks Equity Research | July 23, 2025, 9:57 AM

Vertex Pharmaceuticals, Inc

Zai Lab Limited ADR

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Zai Lab Limited Unsponsored ADR (ZLAB): Free Stock Analysis Report

Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Mentioned In This Article

Vertex Pharmaceuticals, Inc

Zai Lab Limited ADR

Latest News

Apr-01	Vertex Announces US FDA Approval for Label Extensions of ALYFTREK and TRIKAFTA, Expanding Availability of These Medicines to ~95% of All People With CF in the United States VRTX Business Wire
Apr-01	Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy ZLAB +8.13% Business Wire
Mar-28	What are U.S. companies doing with cash? VRTX Investing.com
Mar-25	Maze set to target Vertex as kidney disease drug succeeds in Phase II trial VRTX Clinical Trials Arena
Mar-25	Maze tumbles despite positive data for kidney disease drug VRTX BioPharma Dive
Mar-25	Maze tumbles on positive data for kidney disease drug VRTX BioPharma Dive
Mar-25	Why Maze Therapeutics Plunged 20%-Plus Despite 'Overwhelming Positive' Data VRTX Investor's Business Daily
Mar-24	Anti-Aging Protein Research Takes a Step Forward with Cell Cloning VRTX PR Newswire
Mar-24	The most innovative medicine, therapeutics, and pharmaceutical companies of 2026 VRTX FastCompany
Mar-20	7 Companies That Look Primed to Beat on Earnings VRTX Barrons.com
Mar-18	Block upgraded, Starbucks downgraded: Wall Street's top analyst calls VRTX The Fly
Mar-17	Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC) ZLAB Business Wire
Mar-11	S&P Futures Waver as Middle East Conflict Uncertainty Persists, U.S. Inflation Data in Focus VRTX Barchart
Mar-10	Vertex Just Reported Trial Results for a Kidney Drug. What It Means for the Stock. VRTX +8.31% Barrons.com
Mar-10	Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today VRTX +8.31% StockStory

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)